Chapter

Medical management of diabetic retinopathy

Edited by Paul M Dodson

in Diabetic Retinopathy

Published on behalf of Oxford University Press

ISBN: 9780199544967
Published online May 2011 | e-ISBN: 9780199607235 | DOI: http://dx.doi.org/10.1093/med/9780199544967.003.0016

Series: Oxford Diabetes Library

Medical management of diabetic retinopathy

More Like This

Show all results sharing this subject:

  • Endocrinology and Diabetes

GO

Show Summary Details

Preview

• Medical management is focused on the proven benefit of tight glucose and blood pressure control. • Standard management includes multiple cardiovascular risk factor management with angiotensin receptor blockade, statin and fibrate treatment in addition to aspirin. • Targets to achieve include HbA1c <7%, blood pressure <140/80, and serum cholesterol <4mmol/l. • A number of new trials have demonstrated the beneficial effects on diabetic retinopathy (DR) of fenofibrate (lipid lowering), and Ruboxistaurin ® (protein kinase C inhibition) with reduction of laser treatment and protection of vision. • A landmark study of an angiotensin receptor blocker is due to complete shortly (DIRECT study) which will provide data on the potential benefit of this treatment on both primary and secondary prevention of DR.

Chapter.  2951 words.  Illustrated.

Subjects: Endocrinology and Diabetes

Full text: subscription required

How to subscribe Recommend to my Librarian

Buy this work at Oxford University Press »

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.